Cardiotonic steroids on the road to anti-cancer therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1776, Issue 1, 2007, Pages 32-57

  Mijatovic, Tatjana ^a   Van Quaquebeke, Eric ^a   Delest, Bruno ^a   Debeir, Olivier ^b   Darro, Francis ^a   Kiss, Robert ^c,d  

^a Unibioscreen SA   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d FNRS   (Belgium)

Author keywords

Cardiotonic steroid; Na+ K+ ATPase; New anti cancer drug; Sodium pump targeting

Indexed keywords

16 NORBUFALIN; 2'' OXOVORUSCHARIN; ANTIARIN; BUFADIENOLIDE DERIVATIVE; BUFALIN; CARDENOLIDE DERIVATIVE; CARDIOTONIC AGENT; CERBERIN; CINOBUFAGENIN; CINOBUFAGIN; COROGLAUCIN; CYMARIN; DEACETYLTANGHININ; DIGITOXIN; DIGOXIN; EOUNOSIDE; GLAUCORIN; HELLEBRIN; MARINOBUFAGENIN; NERIANTIN; NERIIN; ODOROSIDE; OLEANDRIN; OUABAIN; PERUVOSIDE; SARMENTOCYMARIN; STEROID; THEVETIN; THEVETOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CARDIAC GLYCOSIDES; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NA(+)-K(+)-EXCHANGING ATPASE; NEOPLASMS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 34548306962     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2007.06.002     Document Type: Review

References (211)

1. +-ATPase as a signal tranducer. Eur. J. Biochem. 269 (2002) 2434-2439
2. Schatzmann H.J. Herzglykoside als hemmstoffe fur den aktiven kalium- und natriumtransport durch die erythrocytenmembran. Helv. Physiol. Pharmacol. Acta 11 (1953) 346-354
3. Gheorghiade M., Adams Jr. K.F., and Colucci W.S. Digoxin in the management of cardiovascular disorders. Circulation 109 (2004) 2959-2964
4. Stenkvist B. Cardenolides and cancer. Anti-Cancer Drugs 12 (2001) 635-636
5. Weidemann H. Na/K-ATPase, endogenous digitalis-like compounds and cancer development-A hypothesis. Front. Biosci. 10 (2005) 2165-2176
6. http://www.clinicaltrials.gov/ct/show/NCT00310882?order=1.
7. Espineda C., Seligson D.B., Ball Jr. J.W., Rao J., Palotie A., Horva S., Huang Y., Shi T., and Rajasekaran A.K. Analysis of the Na/K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer 97 (2003) 1859-1868
8. +)-ATPase alpha 3-isoform and down-regulation of the alpha 1-isoform in human colorectal cancer. FEBS Lett. 563 (2004) 151-154
9. Rajasekaran S.A., Ball Jr. W.J., Bander N.H., Liu H., Pardee J.D., and Rajasekaran A.K. Reduced expression of beta-subunit of Na,K-ATPase in human clear-cell renal cell carcinoma. J. Urol. 62 (1999) 574-580
10. Mijatovic T., Roland I., Van Quaquebeke E., Nilsson B., Mathieu A., Van Vynckt F., Darro F., Blanco G., Facchini V., and Kiss R. The α1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J. Pathol. 212 (2007) 170-179
11. Melero C.P., Medarde M., and San Feliciano A. A short review on cardiotonic steroids and their aminoguanidine analogues. Molecules 5 (2000) 51-81
12. Steyn P.S., and van Heerden F.R. Bufadienolides of plant and animal origin. Nat. Prod. Rep. 15 (1998) 397-413
13. Van Quaquebeke E., Simon G., Andre A., Dewelle J., El Yazidi M., Bruyneel F., Tuti J., Nacoulma O., Guissou P., Decaestecker C., Braekman J.C., Kiss R., and Darro F. Identification of a novel cardenolide (2″-oxovorusharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: Structure-activity relationship analyses. J. Med. Chem. 48 (2005) 849-856
14. Hamed A.I., Plaza A., Balestrieri M.L., Mahalel U.A., Springuel I.V., Oleszek W., Pizza C., and Piacente S. Cardenolide glycosides from Pergularia tomentosa and their proapoptotic activity in Kaposi's sarcoma cells. J. Nat. Prod. 69 (2006) 1319-1322
15. Roy M.C., Chang F.R., Huang H.C., Chiang M.Y., and Wu Y.C. Cytotoxic principles from the formosan milkweed, Asclepias curassavica. J. Nat. Prod. 68 (2005) 1494-1499
16. Kopp B., Krenn L., Draxler M., Hoyer A., Terkola R., Vallaster P., and Robien W. Bufadienolides from Urginea maritima from Egypt. Phytochemistry 42 (1996) 513-522
17. Hamlyn J.M., Blaustein M.P., Bova S., DuCharme D.W., Harris D.W., Mandel F., Mathews M.R., and Ludens J.H. Identification and characterization of ouabain-like compound from human plasma. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 6259-6263
18. Doris P.A., Hayward-Lester A., Bourne D., and Stocco D.M. Ouabain production by cultured adrenal cells. Endocrinology 137 (1996) 533-539
19. Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur. J. Biochem. 269 (2002) 2440-2448
20. Tymiak A.A., Norman J.A., Bolgar M., DiDonato G., Lee H., Parker W.L., Lo L.C., Berova N., Nakanishi K., Haber E., and Haupert G.T. Physico-chemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8189-8193
21. Goto A., Ishiguro T., Yamada K., Ishii M., Yoshioka M., Eguchi C., Shimura M., and Sugimoto T. Isolation of a urinary digitalis-like factor indistinguishable from digoxin. Biochem. Biophys. Res. Commun. 173 (1990) 1093-1101
22. Lichtstein D., Gati I., Samuelov S., Berson D., Rozenman Y., Landau L., and Deutsch J. Identification of digitalis-like compounds in human cataractous lenses. Eur. J. Biochem. 216 (1993) 261-268
23. Hilton P.J., White R.W., Lord G.A., Garner G.V., Gordon D.B., Hilton M.J., Forni L.G., McKinnon W., Ismail F.M., Keenan M., Jones K., and Morden W.E. An inhibitor of the sodium pump obtained from human placenta. Lancet 348 (1996) 303-305
24. Bagrov A.Y., Fedorova O.V., Austin-Lane J.L., Dmitrieva R.I., and Anderson D.E. Endogenous marinobufagenin-like immunoreactive factor and Na+,K+-ATPase inhibition during voluntary hypoventilation. Hypertension 26 (1995) 781-788
25. Sich B., Kirch U., Tepel M., Zidek W., and Schoner W. Pulse pressure correlates in humans with a Proscillaridin A immunoreactive compound. Hypertension 7 (1996) 1073-1078
26. Bagrov A.Y., Dmitrieva R.I., Fedorova O.V., Kazakov G.P., Roukoyatkina N.I., and Shpen V.M. Endogenous marinobufagenin-like immunoreactive substance: a possible endogenous Na,K-ATPase inhibitor with vasoconstrictor activity. Am. J. Hypertens. 14 (1996) 1073-1079
27. Lichtstein D., Steinitz M., Gati I., Samuelov S., Deutsch J., and Orly J. Biosynthesis of digitalis-like compounds in rat adrenal cells: hydroxycholesterol as possible precursor. Life Sci. 62 (1998) 2109-2126
28. Dmitrieva R.I., and Doris P.A. Cardiotonic steroids: potential endogenous sodium pump ligands with diverse function. Exp. Biol. Med. (Maywood) 227 (2002) 561-569
29. Schoner W., and Scheiner-Bobis G. Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer. Semin. Nephrol. 25 (2005) 343-351
30. Fedorova O.V., and Bagrov A.Y. Inhibition of Na/K ATPase from rat aorta by two Na/K pump inhibitors, ouabain and marinobufagenin: evidence of interaction with different alpha-subunit isoforms. Am. J. Hypertens. 10 (1997) 929-935
31. Cassels B.K. Analysis of a Maasai arrow poison. J. Ethnopharmacol. 14 (1985) 273-281
32. Watt J.M., and Breyer-Brandwijk M.G. The Medicinal and Poisonous Plants of Southern and Eastern Africa. 2nd ed. (1962), Livingstone Ltd, Edinburg & London
33. http://www.angelfire.com/journal2/flowers/f.html.
34. Aronson J.K. An Account of the Foxglove and its Medical Uses 1785-1985; Incorporating a facsimile of William Withering's 'An Account of the Foxglove and Some of its Medical Uses' (1785) (1986), Oxford Press
35. Moss R.W. Herbs Against Cancer (1998), Equinox, New York 242-248
36. Mekhail T., Kaur H., Ganapathi R., Budd G.T., Elson P., and Bukowski R.M. Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest. New Drugs 24 (2006) 423-427
37. Rahimtoola S.H. Digitalis therapy for patients in clinical heart failure. Circulation 109 (2004) 2942-2946
38. Skou J.C. The influence of some cations on an adenosinetriphosphatase from peripheral nerves. Biochim. Biophys. Acta 23 (1957) 394-401
39. Blaustein M.P. The interrelationship between sodium and calcium fluxes across cell membranes. Rev. Physiol. Biochem. Pharmacol. 70 (1974) 33-82
40. Demiryurek A.T., and Demiryurek S. Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton. Autacoid Pharmacol. 25 (2005) 35-52
41. Adams Jr. K.F., Gheorghiade M., Uretsky B.F., Patterson J.H., Schwartz T.A., and Young J.B. Clinical benefits of low serum digoxin concentrations in heart failure. J. Am. Coll. Cardiol. 39 (2002) 946-953
42. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336 (1997) 525-533
43. Asano S., Hoshina S., Nakaie Y., Watanabe T., Sato M., Suzuki Y., and Takeguchi N. Functional expression of putative H+-K+-ATPase from guinea pig distal colon. Am. J. Physiol. 275 (1998) C669-C674
44. Swarts H.G.P., Koenderink J.B., Willems P.H.G.M., and De Pont J.J.H.H.M. The non-gastric H,K-ATPase is oligomycin-sensitive and can function as an H+,NH4(+)-ATPase. J. Biol. Chem. 280 (2005) 33115-33122
45. Cougnon M., Planelles G., Crowson M.S., Shull G.E., Rossier B.C., and Jaisser F. The rat distal colon P-ATPase alpha subunit encodes a ouabain-sensitive H+, K+-ATPase. J. Biol. Chem. 271 (1996) 7277-7280
46. Horisberger J.D. Recent insights into the structure and mechanism of the sodium pump. Physiology (Bethesda) 19 (2004) 377-387
47. +-ATPase. J. Biol. Chem. 269 (1994) 19659-19662
48. Blanco G., Melton R.J., Sanchez G., and Mercer R.W. Functional characterization of a testes-specific α subunit isoform of the Na,K-ATPase. Biochemistry 38 (1999) 13661-13669
49. Blanco G. Na,K-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation. Semin. Nephrol. 25 (2005) 292-303
50. Blanco G. The Na/K-ATPase and its isozymes: what we have learned using the baculovirus expression system. Front. Biosci. 10 (2005) 2397-2411
51. Blanco G., Sanchez G., and Mercer R.W. Comparison of the enzymatic properties of the Na,K-ATPase α3β1 and α3β2 isozymes. Biochemistry 34 (1995) 9897-9903
52. Blanco G., Koster J.C., Sanchez G., and Mercer R.W. Kinetic properties of the α2β1 and α2β2 isozymes of the Na,K-ATPase. Biochemistry 34 (1995) 319-325
53. Blanco G., and Mercer R.W. Isozymes of the Na,K-ATPase: heterogeneity in structure, diversity in function. Am. J. Physiol. (Renal Physiol.) 275 (1998) F633-F650
54. Yu C.L., Xie Z.J., Askari A., and Modyanov N.N. Enzymatic properties of human Na,K-ATPase α1β3 isozyme. Arch. Biochem. Biophys. 345 (1997) 143-149
55. Crambert G., Hasler U., Beggah A.T., Yu C., Modyanov N.N., Horisberger J.D., Lelievre L., and Geering G. Transport and pharmacological properties of nine different human Na, K-ATPase isozymes. J. Biol. Chem. 275 (2000) 1976-1986
56. Geering K. Function of FXYD proteins, regulators of Na, K-ATPase. J. Bioenerg. Biomembr. 37 (2005) 387-392
57. Geering K. FXYD proteins: new regulators of Na-K-ATPase. Am. J. Physiol. Renal. Physiol. 290 (2006) F241-F250
58. Li C., Grosdidier A., Crambert G., Horisberger J.D., Michielin O., and Geering K. Structural and functional interaction sites between Na,K-ATPase and FXYD proteins. J. Biol. Chem. 279 (2004) 38895-38902
59. Lubarski I., Pihakaski-Maunsbach K., Karlish S.J., Maunsbach A.B., and Garty H. Interaction with the Na,K-ATPase and tissue distribution of FXYD5 (related to ion channel). J. Biol. Chem. 280 (2005) 37717-37724
60. Beguin P., Crambert G., Monnet-Tschudi F., Uldry M., Horisberger J.D., Garty H., and Geering K. FXYD7 is a brain-specific regulator of Na,K-ATPase alpha 1-beta isozymes. EMBO J. 21 (2002) 3264-3273
61. Mobasheri A., Avila J., Cozar-Castellano I., Brownleader M.D., Trevan M., Francis M.J., Lamb J.F., and Martin-Vasallo P. Na+,K+-ATPase isozyme diversity; comparative biochemistry and physiological implications of novel functional interactions. Biosci. Rep. 20 (2000) 51-91
62. +-ATPase central isoform-specific region: involvement in PKC regulation. Am. J. Physiol. 283 (2002) F1066-F1074
63. Magyar C.E., Wang J., Azuma K.K., and McDonough A.A. Reciprocal regulation of cardiac Na,K-ATPase and Na/Ca exchanger: hypertension, thyroid hormone, development. Am. J. Physiol., Cell Physiol. 269 (1995) C675-C682
64. McDonough A.A., Zhang Y., Shin V., and Frank J.S. Subcellular distribution of sodium pump isoform subunits in mammalian cardiac myocytes. Am. J. Physiol., Cell Physiol. 270 (1996) C1221-C1227
65. Kim C.H., Fan T.H., Kelly P.F., Himura Y., Delehanty J.M., Hang C.L., and Liang C. Isoform-specific regulation of myocardial Na,K-ATPase α-subunit in congestive heart failure. Role of norepinephrine. Circulation 89 (1994) 313-320
66. Schwinger R.H.G., Wang J., Frank K., Muller-Ehmsen J., Brixius K., McDonough A.A., and Erdmann E. Reduced sodium pump a1-, a3-, and b1-isoform protein levels and Na,K-ATPase activity but unchanged Na/Ca exchanger protein levels in human heart failure. Circulation 99 (1999) 2105-2112
67. Espineda C., Chang J.H., Twis J., Rajasekaran S.A., and Rajasekaran A.K. Repression of Na,K-ATPase β1-subunit by the transcription factor Snail in carcinoma. Mol. Biol. Cell 15 (2004) 1364-1373
68. +-ATPase in androgen-dependent and androgen-independent prostate cancer. Br. J. Cancer 8 (1999) 28-36
69. Akopyanz N.S., Broude N.E., Bekman E.P., Marzen E.O., and Sverdlov E.D. Tissue-specific expression of Na,K-ATPase beta-subunit. Does beta 2 expression correlate with tumorigenesis?. FEBS Lett. 289 (1991) 8-10
70. Boukerche H., Su Z.Z., Kang D.C., and Fisher P.B. Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridisation. Gene 343 (2004) 191-201
71. Ernst S.A., and Mills J.W. Autoradiographic localization of tritiated ouabain-sensitive sodium pump sites in ion transporting epithelia. J. Histochem. Cytochem. 28 (1980) 72-77
72. Sweadner K.J. Isozymes of the Na+/K+-ATPase. Biochim. Biophys. Acta 988 (1989) 185-220
73. Lingrel J.B., Orlowski J., Shull M.M., and Price E.M. Molecular genetics of Na,K-ATPase. Prog. Nucleic Acid Res. Mol. Biol. 38 (1990) 37-89
74. Katzmarzyk P.T., Rankinen T., Perusse L., Deriaz O., Tremblay A., Borecki I., Rao D.C., and Bouchard C. Linkage and association of the sodium potassium-adenosine triphosphatase alpha2 and beta1 genes with respiratory quotient and resting metabolic rate in the Quebec Family Study. J. Clin. Endocrinol. Metab. 84 (1999) 2093-2097
75. James P.F., Grupp I.L., Grupp G., Woo A.L., Askew G.R., Croyle M.L., Walsh R.A., and Lingrel J.B. Identification of a specific role for the Na,K-ATPase alpha 2 isoform as a regulator of calcium in the heart. Mol. Cell 3 (1999) 55-63
76. Jaitovich A.A., and Bertorello A.M. Na+,K+-ATPase: an indispensable ion pumping-signaling mechanism across mammalian cell membranes. Semin. Nephrol. 26 (2006) 386-392
77. Kjeldsen K., Bjerregaard P., Richter E.A., Thomsen P.E., and Norgaard A. Na+,K+-ATPase concentration in rodent and human heart and skeletal muscle: apparent relation to muscle performance. Cardiovasc. Res. 22 (1988) 95-100
78. Aydemir-Koksoy A., and Allen J.C. Regulation of Na(+) pump expression by vascular smooth muscle cells. Am. J. Physiol., Heart Circ. Physiol. 280 (2001) H1869-H1874
79. Aydemir-Koksoy A. Na+,K+-ATPase: a review. J. Ank. Med. Sch. 24 (2002) 73-82
80. Arystarkhova E., and Sweadner K.J. Hormonal and neurogenic control of Na-K-ATPase and myosin isoforms in neonatal rat cardiac myocytes. Am. J. Physiol. 273 (1997) C489-C499
81. Sharabani-Yosef O., Bak A., Langzam L., Lui Z., Nir U., Braiman L., Sweadner K.J., and Sampson S.R. Rat skeletal muscle in culture expresses the alpha1 but not the alpha2 protein subunit isoform of the Na+/K+ pump. J. Cell. Physiol. 180 (1999) 236-244
82. +)-ATPase. J. Appl. Physiol. 93 (2002) 1860-1866
83. Ewart H., and Klip A. Hormonal regulation of the Na-K-ATPase: mechanisms underlying rapid and sustained changes in pump activity. Am. J. Physiol., Cell Physiol. 269 (1995) C295-C311
84. Bertorello A.M., Aperia A., Walaas S.I., Nairn A.C., and Greengard P. Phosphorylation of the catalytic subunit of Na+,K(+)-ATPase inhibits the activity of the enzyme. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 11359-11362
85. Aperia A., Holtbäck U., Syren M.-L., Svensson L., Fryckstedt J., and Greengard P. Activation/deactivation of renal Na+,K(+)-ATPase: a final common pathway for regulation of natriuresis. FASEB J. 8 (1994) 436-439
86. Feraille E., Beguin P., Carranza M.L., Gonin S., Rousselot M., Martin P.Y., Favre H., and Geering K. Is phosphorylation of the alpha1 subunit at Ser-16 involved in the control of Na,K-ATPase activity by phorbol ester-activated protein kinase C?. Mol. Biol. Cell 11 (2000) 39-50
87. Barnard M.L., Ridge K.M., Saldias F., Friedman E., Gare M., Guerrero C., Lecuona E., Bertorello A.M., Katz A.I., and Sznajder J.I. Stimulation of the dopamine 1 receptor increases lung edema clearance. Am. J. Respir. Crit. Care Med. 160 (1999) 982-986
88. Lecuona E., Garcia A., and Sznajder J.I. A novel role for protein phosphatase 2A in the dopaminergic regulation of Na,K-ATPase. FEBS Lett. 481 (2000) 217-220
89. Ridge K., Dada L., Lecuona E., Bertorello A., Katz A., Mochly-Rosen D., and Sznajder J. Dopamine-induced exocytosis of the Na,K-ATPase is dependent on the activation of protein kinase C delta and epsilon. Mol. Biol. Cell 13 (2002) 1381-1389
90. Suzuki S., Zuege D., and Berthiaume Y. Sodium-independent modulation of Na(+)-K(+)-ATPase activity by beta-adrenergic agonist in alveolar type II cells. Am. J. Physiol. 268 (1995) L983-L990
91. Ridge K.M., Olivera W.G., Saldias F., Azzam Z., Horowitz S., Rutschman D.H., Dumasius V., Factor P., and Sznajder J.I. Alveolar type 1 cells express the alpha2 Na,K-ATPase, which contributes to lung liquid clearance. Circ. Res. 92 (2003) 453-460
92. Minakata Y., Suzuki S., Grygorczyk C., Dagenais A., and Berthiaume Y. Impact of beta-adrenergic agonist on Na+ channel and Na+-K+-ATPase expression in alveolar type II cells. Am. J. Physiol. 275 (1998) L414-L422
93. Bertorello A.M., and Katz A. Regulation of Na:K pump activity: pathways between receptors and effectors. News Physiol. Sci. 10 (1995) 253-259
94. Ingbar D.H. Lung Na,K-ATPase in pulmonary edema. In: Matthay M.A., and Ingbar D.H. (Eds). Pulmonary Edema (1998), Dekker, New York
95. Therien A.G., and Blostein R. Mechanisms of sodium pump regulation. Am. J. Physiol., Cell Physiol. 279 (2000) C541-C566
96. Olivera W.G., Ciccolella D.E., Barquin N., Ridge K.M., Rutschman D.H., Yeates D.B., and Sznajder J.I. Aldosterone regulates Na,K-ATPase and increases lung edema clearance in rats. Am. J. Respir. Crit. Care Med. 161 (2000) 567-573
97. McDonough A.A., Geering K., and Farley R. The sodium pump needs its subunit. FASEB J. 4 (1990) 1598-1605
98. Pesce L., Guerrero C., Comellas A., Ridge K., and Sznajder J. Beta agonists regulate Na,K-ATPase via novel MAPK/ERK and rapamycin-sensitive pathways. FEBS Lett. 486 (2000) 310-314
99. Gick G., Hatala M., Chon D., and Ismail-Beigi F. Na,K-ATPase in several tissues of the rat: tissue specific expression of subunit mRNAs and enzyme activity. Membr. Biol. 131 (1993) 229-236
100. Devarajan P., Gilmore-Hebert M., and Benz Jr. E.J. Differential translation of the Na,K-ATPase subunit mRNAs. J. Biol. Chem. 267 (1992) 22435-22439
101. Rosen H., Glukhman V., Feldmann T., Fridman E., and Lichtstein D. Cardiac steroids induce changes in recycling of the plasma membrane in human NT2 cells. Mol. Biol. Cell 15 (2004) 1044-1054
102. Price E.M., and Lingrel J.B. Structure-function relationships in the Na,K-ATPase alpha subunit: site directed mutagenesis of glutamine-111 to arginine and asparagine-122 to aspartic acid generates a ouabain-resistant enzyme. Biochemistry 27 (1988) 8400-8408
103. Holzinger F., Frick C., and Wink M. Molecular basis for the insensitivity of the Monarch (Danaus plexippus) to cardiac glycosides. FEBS Lett. 314 (1992) 477-480
104. Labeyrie E., and Dobler S. Molecular adaptation of Chrysochus leaf beetles to toxic compounds in their food plants. Mol. Biol. Evol. 21 (2004) 218-221
105. Lingrel J.B., Arguello J.M., Van Huysse J., and Kuntzweiler T.A. Cation and cardiac glycoside binding sites of the Na,K-ATPase. Ann. N. Y. Acad. Sci. 834 (1997) 194-206
106. Keenan S.M., De Lisle R.K., Welsh W.J., Paula S., and Ball Jr. W.J. Elucidation of the Na+,K+-ATPase digitalis binding site. J. Mol. Graph. Model. 23 (2005) 465-475
107. James P.F., Grupp I.L., Grupp G., Woo A.L., Askew G.R., Croyle M.L., Walsh R.A., and Lingrel J.B. Identification of a specific role for the Na,K-ATPase α2 isoform as a regulator of calcium in the heart. Mol. Cell 3 (1999) 555-563
108. Barcroft L.C., Moseley A.E., Lingrel J.B., and Watson A.J. Deletion of the Na/K-ATPase alpha 1-subunit gene (Atp1a1) does not prevent cavitation of the preimplantation mouse embryo. Mech. Dev. 121 (2004) 417-426
109. Dostanic-Larson I., Van Huysse J.W., Lorenz J.N., and Lingrel J.B. The highly conserved cardiac glycoside binding site of Na,K-ATPase plays a role in blood pressure regulation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15845-15850
110. +-ATPase and biological significance of their cardiac glycoside binding site. Am. J. Physiol., Regul. Integr. Comp. Physiol. 290 (2006) R524-R528
111. Lelievre L.G., Crambert G., and Allen P.D. Expression of functional Na,K-ATPase isozymes in normal human cardiac biopsies. Cell. Mol. Biol. (Noisy-le-grand) 47 (2001) 265-271
112. Lopez Ordieres M.G., and Rodriguez de Lores G. Arnaiz Neurotensin inhibits neuronal Na+,K+-ATPase activity through high affinity peptide receptor. Peptides 21 (2000) 571-576
113. Jewell E.A., and Lingrel J.B. Comparison of the substrate dependence properties of the rat Na,K-ATPase alpha 1, alpha 2 and alpha 3 isoforms expressed in HeLa cells. J. Biol. Chem. 266 (1991) 16925-16930
114. Horowitz B., Eakle K.A., Scheiner-Bobis G., Randolph G.R., Chen C.Y., Hitzeman R.A., and Farley R.A. Synthesis and assembly of functional mammalian Na,K-ATPase in yeast. J. Biol. Chem. 265 (1990) 4189-4192
115. Blanco G., Xie Z.J., and Mercer R.W. Functional expression of the α2 and α3 isoforms of the Na,K-ATPase in baculovirus-infected insect cells. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 1824-1828
116. Segall L., Daly S.E., and Blostein R. Mechanistic basis for kinetic differences between the rat α1, α2, and α3 isoforms of the Na,K-ATPase. J. Biol. Chem. 276 (2001) 31535-31541
117. Müller-Ehmsen J., Juvvadi P., Thompson C.B., Tumyan L., Croyle M., Lingrel J.B., Schwinger R.H., McDonough A.A., and Farley R.A. Ouabain and substrate affinities of human Na(+)-K(+)-ATPase alpha(1)beta(1), alpha(2)beta(1), and alpha(3)beta(1) when expressed separately in yeast cells. Am. J. Physiol., Cell Physiol. 281 (2001) C1355-C1364
118. Schmidt T.A. Human myocardial and skeletal muscular Na,K-ATPase in relation to digoxin therapy of heart failure. Dan. Med. Bull. 44 (1997) 499-521
119. Qiu L.Y., Krieger E., Schaftenaar G., Swarts H.G., Willems P.H., De Pont J.J., and Koenderink J.B. Reconstruction of the complete ouabain-binding pocket of Na,K-ATPase in gastric H,K-ATPase by substitution of only seven amino acids. J. Biol. Chem. 280 (2005) 32349-32355
120. Qiu L.Y., Swarts H.G., Tonk E.C., Willems P.H., Koenderink J.B., and De Pont J.J. Conversion of the low affinity ouabain-binding site of non-gastric H,K-ATPase into a high affinity binding site by substitution of only five amino acids. J. Biol. Chem. 281 (2006) 13533-13539
121. Scheiner-Bobis G. The sodium pump. Its molecular properties and mechanics of ion transport. Eur. J. Biochem. 269 (2002) 2424-2433
122. Lytton J., Lin J.C., and Guidotti G. Identification of two molecular forms of (Na+,K+)-ATPase in rat adipocytes. Relation to insulin stimulation of the enzyme. J. Biol. Chem. 260 (1985) 1177-1184
123. Skou J.C. The Na-K pump. News Physiol. Sci. 7 (1992) 95-100
124. +-ATPase activity. J. Appl. Physiol. 87 (1999) 715-721
125. Gao J., Wymore R.S., Wang Y., Gaudette G.R., Krukenkamp I.B., Cohen I.S., and Mathias R.T. Isoform-specific stimulation of cardiac Na/K pumps by nanomolar concentrations of glycosides. J. Gen. Physiol. 119 (2002) 297-312
126. +-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol. Interv. 3 (2003) 157-168
127. Haas M., Askari A., and Xie Z. Involvement of Src and epidermal growth factor receptor in the signal transducing function of Na+/K+-ATPase. J. Biol. Chem. 275 (2000) 27832-27837
128. Haas M., Wang H., Tian J., and Xie Z. Src-mediated interceptor cross-talk between the Na+-K+-ATPase and the EGF receptor relays the signal from ouabain to mitogen-activated protein kinases. J. Biol. Chem. 277 (2002) 18694-18702
129. Manna S.K., Sah N.K., Newman R.A., Cisneros A., and Aggarwal B.B. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1 and c-Jun NH2-terminal kinase. Cancer Res. 60 (2000) 3838-3847
130. Aizman O., Uhlen P., Lal M., Brismar H., and Apeira A. Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13420-13424
131. Sreenivasan Y., Sarkar A., and Manna S.K. Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem. Pharmacol. 66 (2003) 2223-2239
132. Mijatovic T., Op De Beek A., Van Quaquebeke E., Dewelle J., Darro F., de Launoit Y., and Kiss R. The cardenolide UNBS1450 is able to deactivate NF-κB-mediated cytoprotective effects in human non-small-cell-lung cancer (NSCLC) cells. Mol. Cancer Ther. 5 (2006) 391-399
133. +-ATPase. J. Biol. Chem. 279 (2004) 17250-17259
134. 2+]i in rat cardiac myocytes. Am. J. Physiol., Heart Circ. Physiol. 281 (2001) H1899-H1907
135. 2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res. 60 (2000) 3807-3812
136. Trevisi L., Visentin B., Cusinato F., Pighin I., and Luciani S. Antiapoptotic effect of ouabain on human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 321 (2004) 716-721
137. Taurin S., Dulin N.O., Pchejetski D., Grygorczyk R., Tremblay J., Hamet P., and Orlov S.N. c-Fos expression in ouabain-treated vascular smooth muscle cells from rat aorta: evidence for an intracellular-sodium-mediated, calcium-independent mechanism. J. Physiol. 15 (2002) 835-847
138. Mijatovic T., Mathieu V., Gaussin J.-F., De Neve N., Ribaucour F., Van Quaquebeke E., Dumont E.P., Darro F., and Kiss R. Cardenolide-induced lysosomal membrane permeabilization contributes therapeutic benefits in experimental human non-small-cell-lung cancers. Neoplasia 8 (2006) 402-412
139. Lin H., Juang J.L., and Wang P.S. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J. Biol. Chem. 279 (2004) 29302-29307
140. Kometiani P., Liu L., and Askari A. Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol. Pharmacol. 67 (2005) 929-936
141. Aydemir-Koksoy A., Abramowitz J., and Allen J.C. Ouabain induced signaling and vascular smooth muscle cell proliferation. J. Biol. Chem. 276 (2001) 46605-46611
142. Rajasekaran S.A., Palmer L.G., Quan K., Harper J.F., Ball Jr. W.J., Bander N.H., Peralta Soler A., and Rajasekaran A.K. Na,K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility. Mol. Biol. Cell 12 (2001) 279-295
143. Rajasekaran A.K., and Rajasekaran S.A. Role of Na-K-ATPase in the assembly of tight junctions. Am. J. Physiol., Renal Physiol. 285 (2003) F388-F396
144. Rajasekaran S.A., Barwe S.P., and Rajasekaran A.K. Multiple functions of Na,K-ATPase in epithelial cells. Semin. Nephrol. 25 (2005) 328-334
145. Nelson W.J., and Veshnock P.J. Ankyrin binding to Na+,K+-ATPase and implications for the organization of membrane domains in polarized cells. Nature (Lond.) 328 (1987) 533-536
146. Nelson W.J., and Hammerton R.W. A membrane-cytoskeletal complex containing Na+,K+-ATPase, ankyrin, and fodrin in Madin-Darby canine kidney (MDCK) cells: implications for the biogenesis of epithedial cell polarity. J. Cell Biol. 108 (1989) 893-902
147. Morrow J.S., Cianci C.D., Ardito T., Mann A.S., and Kashgarian M. Ankyrin fodrin to the a subunit of Na+,K+-ATPase in Madin-Darby canine kidney cells in intact renal tubule cells. J. Cell Biol. 108 (1989) 455-465
148. Kaplan J.G. Membrane cation transport and the control of proliferation of mammalian cells. Annu. Rev. Physiol. 40 (1978) 19-41
149. Shen S.S., Hamamoto S.T., Bern H.A., and Steinhardt R.A. Alteration of sodium transport in mouse mammary epithelium associated with neoplastic transformation. Cancer Res. 38 (1978) 1356-1361
150. Gonta-Gabriec K., Rossowski W., and Szumiel I. Properties of Na/K-ATPase and alkaline phosphatase alter during spontaneous and radiation-induced leukemogenesis in mice. Neoplasma 33 (1986) 141-155
151. Davies R.J., Sandle G.I., and Thompson S.M. Inhibition of the Na+,K(+)-ATPase pump during induction of experimental colon cancer. Cancer Biochem. Biophys. 12 (1991) 81-94
152. Chen J.Q., Contreras R.G., Wang R., Fernandez S.V., Shoshani L., Russo I.H., Cereijido M., and Russo J. Sodium/potassium ATPase (Na(+), K(+)-ATPase) and ouabain/related cardiac glycosides: a new paradigm for development of anti-breast cancer drugs?. Breast Cancer Res. Treat. 96 (2006) 1-15
153. Imai K., and Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev., Cancer 6 (2006) 714-727
154. Meric-Bernstam F., and Hung M.C. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin. Cancer Res. 12 (2006) 6326-6330
155. +-ATPase with an original mechanism of action. Biochem. Pharmacol. 66 (2003) 2169-2176
156. Okamoto Y., Ojika M., Suzuki S., Murakami M., and Sakagami Y. Iantherans A and B, unique dimeric polybrominated benzofurans as Na,K-ATPase inhibitors from a marine sponge, Ianthella sp. Bioorg. Med. Chem. 9 (2001) 179-183
157. Fu Y.F., Zhang S.L., Lu Z.M., and Wang W. Effects of gossypol on the activity of kidney (sodium + potassium)-ATPase and the functions of erythrocyte membrane. Contraception 37 (1988) 179-184
158. Lei X., Chen Y., Du G., Yu W., Wang X., Qu H., Xia B., He H., Mao J., Zong W., Liao X., Mehrpour M., Hao X., and Chen Q. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J. 20 (2006) 2147-2149
159. Haspel H.C., Corin R.E., and Sonenberg M. Effect of gossypol on erythrocyte membrane function: specific inhibition of inorganic anion exchange and interaction with band 3. J. Pharmacol. Exp. Ther. 234 (1985) 575-583
160. Konac E., Ekmekci A., Yurtcu E., and Ergun M.A. An in vitro study of cytotoxic effects of gossypol on human epidermoid larynx carcinoma cell line (HEp-2). Exp. Oncol. 27 (2005) 81-83
161. Zhang M., Liu H., Tian Z., Griffith B.N., Ji M., and Li Q.Q. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sci. 80 (2007) 767-774
162. Gorshkov B.A., Gorshkova I.A., and Makarieva T.N. Inhibitory characteristics of 3,5-dibromo-1-acetoxy-4-oxo-2,5-cyclohexadien-1-acetonitrile, a semisynthetic derivative of aeroplysinin-1 from sponges (Aplysinidae) on sodium-potassium ATPase. Toxicon 22 (1984) 441-449
163. Okamoto Y., Nitanda N., Ojika M., and Sakagami Y. Aplysiallene, a new bromoallene as an Na, K-ATPase inhibitor from the sea hare, Aplysia kurodai. Biosci. Biotechnol. Biochem. 65 (2001) 474-476
164. Ngamrojnavanich N., Sirimongkon S., Roengsumran S., Petsom A., and Kamimura H. Inhibition of Na+, K+-ATPase activity by (-)-ent-kaur-16-en-19-oic acid and its derivatives. Planta Med. 69 (2003) 555-556
165. Mongelli E., Pomilio A.B., Sanchez J.B., Guerra F.M., and Massanet G.M. ent-Kaur-16-en-19-oic acid, a KB cells cytotoxic diterpenoid from Elaeoselinum foetidum. Phytother. Res. 16 (2002) 387-388
166. Stenkvist B. Is digitalis a therapy for breast carcinoma?. Oncol. Rep. 6 (1999) 493-496
167. Haux J. Digitoxin is a potential anticancer agent for several types of cancer. Med. Hypotheses 153 (1999) 543-548
168. Stenkvist B., Westman-Naeser S., Holmquist J., Nordin B., Bengtsson E., Vegelius J., Eriksson O., and Fox C.H. Computerized nuclear morphometry as an objective method for characterizing human cell populations. Cancer Res. 38 (1978) 4688-4697
169. Stenkvist B., Bengtsson E., Eklund G., Eriksson O., Holmquist J., Nordin B., and Westman-Naeser S. Evidence of a modifying influence of heart glycosides on the development of breast cancer. Anal. Quant. Cytol. 2 (1980) 49-54
170. Stenkvist B., Pengtsson E., Dahlquist B., Eriksson O., Jarkrans T., and Nordin B. Cardiac glycosides and breast cancer, revisited. N. Engl. J. Med. 306 (1982) 484
171. Goldin A.G., and Safa A.R. Digitalis and cancer. Lancet 1 (1984) 1134
172. Haux J., Klepp O., Spigset O., and Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 1 (2001) 11
173. Huang Y.T., Chueh S.C., Teng C.M., and Guh J.H. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem. Pharmacol. 67 (2004) 727-733
174. Yeh J.H., Huang W.J., Kan S.F., and Wang P.S. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J. Urol. 166 (2001) 1937-1942
175. Yeh J.H., Huang W.J., Kan S.F., and Wang P.S. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54 (2003) 112-124
176. Frese S., Frese-Schaper M., Andres A.C., Miescher D., Zumkehr B., and Schmid R.A. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res. 66 (2006) 5867-5874
177. Pathak S., Multani A.S., Narayan S., Kumar V., and Newman R.A. Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer Drugs 11 (2000) 455-463
178. Sreenivasan Y., Raghavendra P.B., and Manna S.K. Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. J. Clin. Immunol. 26 (2006) 308-322
179. Newman R.A., Yang P., Hittelman W.N., Lu T., Ho D.H., Ni D., Chan D., Vijjeswarapu M., Cartwright C., Dixon S., Felix E., and Addington C. Oleandrin-mediated oxidative stress in human melanoma cells. J. Exp. Ther. Oncol. 5 (2006) 167-181
180. Lopez-Lazaro M., Pastor N., Azrak S.S., Ayuso M.J., Austin C.A., and Cortes F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J. Nat. Prod. 68 (2005) 1642-1645
181. Bielawski K., Winnicka K., and Bielawska A. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol. Pharm. Bull. 29 (2006) 1493-1497
182. Watabe M., Nakajo S., Yoshida T., Kuroiwa Y., and Nakaya K. Treatment of U937 cells with bufalin induces the translocation of casein kinase 2 and modulates the activity of topoisomerase II prior to the induction of apoptosis. Cell Growth Differ. 8 (1997) 871-879
183. Johnson P.H., Walker R.P., Jones S.W., Stephens K., Meurer J., Zajchowski D.A., Luke M.M., Eeckman F., Tan Y., Wong L., Parry G., Morgan Jr. T.K., McCarrick M.A., and Monforte J. Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells. Mol. Cancer Ther. 14 (2002) 1293-1304
184. Lefranc F., Brotchi J., and Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 23 (2005) 2411-2422
185. Florkiewicz R.Z., Anchin J., and Baird A. The inhibition of fibroblast growth factor-2 export by cardenolides implies a novel function for the catalytic subunit of Na+,K+-ATPase. J. Biol. Chem. 273 (1998) 544-551
186. Smith J.A., Madden T., Vijjeswarapu M., and Newman R.A. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem. Pharmacol. 62 (2001) 469-472
187. Zhang L.S., Nakaya K., Yoshida T., and Kuroiwa Y. Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. 178 (1991) 686-693
188. Numazawa S., Shinoki M.A., Ito H., Yoshida T., and Kuroiwa Y. Involvement of Na+,K(+)-ATPase inhibition in K562 cell differentiation induced by bufalin. J. Cell. Physiol. 160 (1994) 113-120
189. Daniel D., Susal C., Kopp B., Opelz G., and Terness P. Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int. Immunopharmacol. 3 (2003) 1791-1801
190. Prassas I., Paliouras M., and Diamandis E.P. High-throughput screening for modulators of tissue-kallikrein expression. American Association for Cancer Research (AACR) Annual Meeting, Los Angeles, USA, April 14-18th (2007)
191. Simpson C.D., Mawji I.A., Williams M.A., Hurren R., Beheshti-Zavareh R., and Schimmer A.D. A high throughput cell-based screen identifies inhibitors of the Na+/K+ ATPase pump as sensitizers to anoikis and inhibitors of metastasis. American Association for Cancer Research (AACR) Annual Meeting, Los Angeles, USA, April 14-18th (2007)
192. Verheye-Dua F., and Bohm L. Influence of ouabain on cell inactivation by irradiation. Strahlenther. Onkol. 172 (1996) 156-161
193. +-ATPase inhibitor, ouabain accentuates irradiation damage in human tumour cell lines. Radiat. Oncol. Investig. 6 (1998) 109-119
194. Lawrence T.S. Ouabain sensitizes tumor cells but not normal cells to radiation. Int. J. Radiat. Oncol. Biol. Phys. 15 (1988) 953-958
195. Nasu S., Milas L., Kawabe S., Raju U., and Newman R. Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett. 185 (2002) 145-151
196. Inada A., Nakanishi T., Konoshima T., Kozuka M., Tokuda H., Nishino H., and Iwashima A. Anti-tumor promoting activities of natural products. II. Inhibitory effects of digitoxin on two-stage carcinogenesis of mouse skin tumors and mouse pulmonary tumors. Biol. Pharm. Bull. 16 (1993) 930-931
197. Svensson A., Azarbayjani F., Backman U., Matsumoto T., and Christofferson R. Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res. 25 (2005) 207-212
198. Afaq F., Saleem M., Aziz M.H., and Mukhtar H. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion markers in CD-1 mouse skin by oleandrin. Toxicol. Appl. Pharmacol. 195 (2004) 361-369
199. Lefranc F., Mijatovic T., Camby I., Gailly P., Van Quaquebeke E., Darro F., and Kiss R. The binding of the UNBS1450 cardenolide to the sodium pump in human glioblastoma (GBM) cells dramatically impairs both their migration and proliferation properties. American Association for Cancer Research (AACR) Annual Meeting, Washington DC, USA, April 1-5 (2006)
200. Mijatovic T., Mathieu V., De Nève N., Van Quaquebeke E., Darro F., and Kiss R. Cardenolide-mediated nucleolar disorganisation contributes therapeutic benefits in subcutaneous and orthotopic xenograft models of human refractory prostate cancers. American Association for Cancer Research (AACR) Annual Meeting, Washington DC, USA, April 1-5 (2006)
201. http://www.clinicaltrials.gov/ct/show/NCT00281021?order=1.
202. Gao J., Wymore R., Wymore R.T., Wang Y., McKinnon D., Dixon J.E., Mathias R.T., Cohen I.S., and Baldo G.J. Isoform-specific regulation of the sodium pump by alpha- and beta-adrenergic agonists in the guinea-pig ventricle. J. Physiol. 516 (1999) 377-383
203. Rose A.M., Qazzaz H.M., Zolotarjova N., Mellett B.J., Martin A.W., and Valdes Jr. R. Sodium pump isoforms in xenotransplantation: importance of biochemical compatibility. Clin. Chem. 46 (2000) 234-241
204. +-ATPase isoforms in myocardium. Isoform change in deoxycorticosterone acetate-salt hypertension. Circ. Res. 74 (1994) 669-678
205. Schwartz A., and Petrashevskaya N.N. The importance of calcium in interpretation of NaK-ATPase isoform function in the mouse heart. Cardiovasc. Res. 51 (2001) 9-12
206. Mudge Jr. G.H., Lloyd B.L., Greenblatt D.J., and Smith T.W. Inotropic and toxic effects of a polar cardiac glycoside derivative in the dog. Circ. Res. 43 (1978) 847-854
207. Beyda E.J., Jung M., and Bellet S. Effect of hypothermia on the tolerance of dogs to digitalis. Circ. Res. 9 (1961) 129-135
208. Lynch J.J., DiCarlo L.A., Montgomery D.G., Hassan T., and Lucchesi B.R. Electrophysiologic actions of pirmenol in dogs with recent myocardial infarction. Am. Heart J. 112 (1986) 752-758
209. Lynch J.J., Simpson P.J., Gallagher K.P., McClanahan T.B., Lee K.A., and Lucchesi B.R. Increase in experimental infarct size with digoxin in a canine model of myocardial ischemia-reperfusion injury. Am. Heart J. 115 (1988) 1171-1182
210. Maixent J.-M., Charlemagne D., de la Chapelle B., and Lelievre L.G. Two Na,K-ATPase isoenzymes in canine cardiac myocytes. Molecular basis of inotropic and toxic effects of digitalis. J. Biol. Chem. 262 (1987) 6842-6848
211. Langenhan J.M., Peters N.R., Guzei I.A., Hoffmann F.M., and Thorson J.S. Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12305-12310